Your browser doesn't support javascript.
loading
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Joseph, Richard W; Elassaiss-Schaap, Jeroen; Kefford, Richard; Hwu, Wen-Jen; Wolchok, Jedd D; Joshua, Anthony M; Ribas, Antoni; Hodi, F Stephen; Hamid, Omid; Robert, Caroline; Daud, Adil; Dronca, Roxana; Hersey, Peter; Weber, Jeffrey S; Patnaik, Amita; de Alwis, Dinesh P; Perrone, Andrea; Zhang, Jin; Kang, S Peter; Ebbinghaus, Scot; Anderson, Keaven M; Gangadhar, Tara C.
Afiliação
  • Joseph RW; Department of Medical Oncology, Mayo Clinic, Jacksonville, Florida. joseph.richard@mayo.edu.
  • Elassaiss-Schaap J; PD-value, Pharmacometrics, Utrecht, the Netherlands.
  • Kefford R; Department of Clinical Medicine, Macquarie University, Sydney, Australia.
  • Hwu WJ; Department of Clinical Medicine, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia, Sydney, Australia.
  • Wolchok JD; Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Joshua AM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ribas A; Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Hodi FS; Department of Medical Oncology, Kinghorn Cancer Centre, Sydney, Australia.
  • Hamid O; Department of Medicine, University of California, Los Angeles, Los Angeles, California.
  • Robert C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Daud A; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, California.
  • Dronca R; Gustave Roussy and Paris-Sud University, Service de Dermatologie, Villejuif, France.
  • Hersey P; Department of Hematology/Oncology, University of California, San Francisco, San Francisco, California.
  • Weber JS; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
  • Patnaik A; Department of Medical Oncology, University of Sydney, Sydney, Australia.
  • de Alwis DP; Department of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
  • Perrone A; Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio, Texas.
  • Zhang J; Department of Oncology Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey.
  • Kang SP; Department of Oncology Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey.
  • Ebbinghaus S; Department of Biostatistics and Research Decision Sciences, Merck & Co., Inc., Kenilworth, New Jersey.
  • Anderson KM; Department of Oncology Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey.
  • Gangadhar TC; Department of Oncology Clinical Research, Merck & Co., Inc., Kenilworth, New Jersey.
Clin Cancer Res ; 24(20): 4960-4967, 2018 10 15.
Article em En | MEDLINE | ID: mdl-29685882
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article